A9145is a new adenine-containing antifungal antibiotic. A9145showedweakin vitro activity against Candida albicans in Sabouraud's medium, but was strongly inhibitory in a chemically defined medium. Viability counts of C. albicans following extended exposure to A9145 indicated a fungistatic action. Following a lOOmg/kg dose, a peak of64^g/ml of A9145 activity was detected in mouse blood. Administration of 10 mg/kg for 3 days extended the survival time of mice infected with C. albicans 128 % ; equivalent doses of amphotericin B extended survival time \\2%. A total dose of 31.25mg/kg administered over a 5-day period reduced by 400-fold the number of Candida recovered from kidney homogenates of infected mice. A combination of amphotericin B and A9145 caused a possible synergistic effect against C. albicans in vitro and an additive effect in vivo.
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Polyene antibiotics have been useful chemotherapeutic agents for deep-seated mycoses. Because of toxicity, polyene antibiotics, such as amphotericin B, are not ideal antifungal agents1}. Nonpolyenic compoundssuch as a polypeptide antibiotic, saramycetin, and 5-fluorocytosine are promising antifungal agents. Saramycetin is active against Histoplasma capsulatum and 5-fluorocytosine is active against Candida albicans and Cryptococcus neoformans2>B\A newnon-polyenic compound, clotrimidazole (bis-phenyl-(2-chlorophenyl)-l-imidazolyl-methane), has been reported to be effective against C. albicans by oral administration0. The continuing discovery of compounds of diverse chemical types with useful antifungal activity is encouraging.
A new adenine-containing nucleoside antibiotic, A9145, has been discovered and isolated5). The in vitro and in vivo activity of A9145against pathogenic fungi is described in this report.
Materials and Methods
In Vitro Studies. All cultures were maintained on Sabouraud's agar as modified by Emmons6). The minimal inhibitory concentration (MIC) of A9145 was determined using the broth-dilution technique described previously7). Cultures of Histoplasma capsulatum 26 and Blastomyces dermatitidis B6059were incubated at 37°C while all other cultures were maintained at 30°C. Susceptibility studies on Candida species were also performed on filter-sterilized Yeast nitrogen base (Difco) supplemented with dextrose (lO g/liter) and asparagine (1.5 g/liter). The fungistatic effect of A9145 against C. albicans was determined by inoculating Sabouraud's or Yeast nitrogen base broth containing A9145 with inocula differing in concentration by one log. Viable cell counts were performed by plating techniques described previously8). The antifungal activity ofA9145 in blood was determined by a disc diffusion assay9). Saccharomycespastorianus, the assay organism, permitted the detection of 1 fjtg of activity per ml.
In Vivo Studies. In vivo evaluation of A9145in mice infected intravenously with 1.5xlO6 C. H. capsulatum 26 was performed as described previously10>n\ Mice were X-irradiated with 400r 24 hours prior to infection which was administered in the lateral tail vein with 0.1 ml cell suspension. Antifungal agents were suspended in 0.125 %methyl-cellulose (Dow Chemical Company) and administered in 0.25ml volumes to 6 infected mice and 2 uninfected toxicity control animals. All treatments were administered subcutaneously, unless ortherwise noted, at 0 and 2-hours post-infection on the first day of treatment ; subsequent treatments on successive days were at 2 hour intervals. The average survival time of treated and untreated animals was compared after 7 days. All animals surviving at 7 days post-infection were arbitrarily given an average survival time of 8 days. The significance of A9145treatments was determined by the t test and P values. Anindication of the virulence of C. albicans A-26 in each experimental infection was obtained by determining the number of LD50's12). All doses of A9145 administered in this study did not cause death of uninfected toxicity control animals. The effect of A9145on the recovery of Candida cells from kidney homogenates was performed in unirradiated mice intravenously infected with 105 viable cells13). After 5 days treatment with A9145, kidney homogenates were plated on Sabouraud's agar, incubated at 30°C for 48 hours, and the number of cells recovered per gram of kidney determined7).
Results
In Sabouraud's broth, A9145 did not show potent antifungal activity against a number of pathogenic fungi (Table 1) . In a defined medium, 1.56^3.12[ig ofA9145 per ml were inhibitory to C. albicans; other Candida species were less susceptible ( Table 2 ). The growth of all Candida isolates obtained in a defined mediumwas comparable to that obtained in Sabouraud's medium. Attempts to identify, by reversal studies, the factor in the complex mediumresponsible for reduction of A9145 activity have not been successful. Exposure to 1 mg/ml of A9145 in Sabouraud's broth produced little change in the viable cell count of C. albicans inocula compared to growth of controls in antibiotic-free medium (Fig. 1) . A similar fungistatic effect was achieved with 10 or 25ftg/ml of A9145 in Yeast nitrogen base broth (Fig. 2) . Following 3 and 4 days exposure to A9145 in the defined medium, 25 //g/ml showed a greater reduction in viable counts than 10 /*g of the antibiotic.
The MICofamphotericin B or A9145 caused a greater than 1 log reduction in the viable cell count of C. albicans (Table 3) (Fig. 3) . At90minutes, approximately 1 fjtg ofA9145 activity was found. A9145 activity was detected in mouseurine and followed the same trend as that seen in blood.
A9145 administered twice daily for 3 days at40,20, and 10mg/kgper day significantly increased the survival time of mice infected with C. albicans A-26 (Table 4) .
Since activity increased with a reduction in dose leves, it would appear that the 40 and 20mg/kg doses are close to a threshold of toxicity. The 10mg/kg dose extended survival 124 % beyond controls which was comparable to a 200mg/kg dose of amphotericin B. Two daily doses of 10, 5, and 2.5mg/kg per day for 3 days significantly increased survival time;
decreasing activity was observed with a decreasing dose of antibiotic ( Table 5 ). The \2%% extension of survival obtained with daily doses of A9145 was comparable to that achieved with amphotericin B. The effectiveness of A9145 by intraperitoneal administration compared with that obtained subcutaneously, while oral doses, though significant, were less effective. A total dose of 40~50 mg/kg of A9145 was ineffective against C. neoformans, B. dermatitidis, and H. capsulatum infected mice. The recovery of Candida cells from kidney homogenates of infected mice was reduced by A9145 (Table 6) , Following a total dose of 31.25 mg/kg for 5 days, the number of Candida cells recovered was reduced nearly 400-fold from untreated controls. In comparison, amphotericin B at the same level lowered the number of Candida cells 100-fold.
The effectiveness of A9145 and amphotericin B administered singly and in combination was Table 5 . In vivo activity of A9145 against C. albicans * P<0.05by"t"test Table 6 . The effect of A9145 on recovery of Candida from mouse kidney homogenates * Determined from a single count investigated (Table 7) . Multiple doses of A9145 were administered to maintain a high level of activity in blood, while a single dose of the longer lasting amphotericin B was administered. A9145 alone extended survival 61 % beyond controls, while amphotericin B alone extended survival 55 % \ the combination of both antibiotics resulted in a 132 %extension of survival time.
A9145 showed muchgreater in vitro activity against C. albicans in a defined mediumthan in Sabouraud's medium. Further study of the structure of A9145may provide clues for the identity of a factor or factors responsible for diminished antibiotic activity in a complex medium. A fungistatic action was achieved following four days exposure to A9145 with a 40 to 100-fold lower concentration in the defined mediumcompared to Sabouraud's medium.
Subinhibitory concentrations of A9 145 combined with an inhibitory concentration of amphotericin Bresulted in a significant reduction in viable cell count as comparedwith either antibiotic alone. The greater than 2log reduction of viable cells suggests a synergistic action between the two antifungal antibiotics.
Lowmultiple doses of A9145were most effective against C. albicans infected mice. The advantage of this treatment regimen was explained when blood and urine activities were found to peak very soon after injection followed by rapid elimination. Survival time of infected mice treated with A9145 compared favorably with amphotericin B treated controls. Efficacy of this antibiotic was demonstrated in the kidney, the target organ of Candida infections. Combination studies with A9145 and amphotericin B doubled the survival of infected mice and indicated the effectiveness of combined therapy for two antifungal antibiotics.
Although the spectrum of A9145 antifungal activity appears limited to C. albicans, a number of isolates of other pathogenic fungi should be studied for susceptibility to this antibiotic.
